Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:26 PM ET 10-Q
Financial Results Ionic Digital Inc. IOND

Ionic Digital Q3 2026 Results: Turns Profitable, Net Income $17.4M

Ionic Digital Inc. reported a significant shift in its business model, with digital infrastructure leasing revenue of $131.7 million for the nine months ended September 30, 2026, surpassing its cryptocurrency mining revenue. Despite a net loss of $30.9 million for the nine-month period, the company achieved a net income of $17.4 million in the third quarter, bolstered by a $73.2 million gain on the fair value of cryptocurrency assets.

Key figure
Net income $17.4M
4:26 PM ET 10-Q
Financial Results Vivos Inc RDGL

Vivos Q3 2026 Results: Net Loss of $732K, Loss Widens

Vivos Inc. reported a net loss of $2,746,628 for the nine months ended September 30, 2026, compared to a loss of $1,987,503 in the prior year period, driven largely by a $847,628 non-operating loss on share issuances. While revenues increased significantly to $101,368 from $43,627, the company continues to operate with a substantial accumulated deficit of over $91 million.

Key figure
Net loss $732K
4:26 PM ET 8-K
Reverse Stock Split Kala BIO, Inc. KALA

Kala BIO Reverse Stock Split

KALA BIO filed a Certificate of Amendment to effect a 1-for-30 reverse stock split of its common stock, effective November 13, 2026. The split will reduce the number of outstanding shares from approximately 19.3 million to approximately 644,659 to meet market requirements. Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market on November 16, 2026.

4:26 PM ET 8-K
Financial Results Nektar Therapeutics NKTR

Nektar Therapeutics Financial Results

Nektar Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $952.9 million and the initiation of Phase 3 registrational trials for rezpegaldesleukin in atopic dermatitis. The company reported a net loss of $55.7 million on revenue of $9.4 million, with R&D expenses increasing to support its late-stage clinical programs.

Term
Q3 2026

“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development. We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned.”

Howard Robin, President and Chief Executive Officer of Nektar
4:25 PM ET 10-Q
Financial Results Innovate Corp. VATE

Innovate Q3 2026 Results: Turns Profitable, Net Income $26.5M

INNOVATE Corp. reported a significant turnaround for the third quarter of 2026, with net income attributable to common stockholders of $15.8 million compared to a net loss of $9.4 million in the prior year. Revenue grew to $495.5 million for the quarter, driven by operations and a $32.9 million gain on the sale of a controlling interest in a subsidiary.

Key figure
Net income $26.5M
4:25 PM ET 8-K
Nasdaq/NYSE Compliance Notice Beneficient BENF

Beneficient Nasdaq/NYSE Compliance Notice

Beneficient received a deficiency notice from Nasdaq on November 5, 2026, because its market value of listed securities (MVLS) fell below the $35 million minimum requirement for 30 consecutive business days. The company has until May 4, 2027, to regain compliance by maintaining an MVLS of at least $35 million for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's Class A common stock (BENF) or warrants (BENFW).

Counterparty
Nasdaq
Term
180 days
4:25 PM ET Form 4
Insider Buying BRT Apartments Corp. BRT

BRT Apartments Chairman of the Board Matthew J. Gould Buys $39.4K of Stock

Matthew J. Gould, Chairman of the Board, bought 3,000 shares of BRT Apartments Corp. at $13.14 a share, worth $39.4K in total on Nov 9, 2026. Shares held after the trade: 3,000.

Value
$39.4K
Shares
3,000
Price
$13.14
Role
Chairman of the Board
Trade date
Nov 9, 2026
4:25 PM ET 8-K/A
Shareholder Meeting Tapestry, Inc. TPR

Tapestry Shareholder Meeting

Tapestry, Inc. held its 2026 Annual Meeting of Stockholders where eleven directors were elected to serve until the 2027 meeting. Stockholders also ratified Deloitte & Touche LLP as the independent auditor, approved executive compensation on an advisory basis, and approved a stockholder proposal regarding action by written consent.

4:25 PM ET Form 4
Insider Selling Motorola Solutions, Inc. MSI

Motorola Solutions Chairman and CEO Gregory Q. Brown Sells $13.2M of Stock

Gregory Q. Brown, Chairman and CEO, sold 25,000 shares of Motorola Solutions, Inc. at $521.30 to $529.73 a share (average $526.14) in 10 transactions, worth $13.2M in total on Nov 10, 2026. Shares held after the trade: 66,769 (-0.2%).

Value
$13.2M
Shares
25,000
Average price
$526.14
Role
Chairman and CEO
Holding change
-0.2%
Trade date
Nov 10, 2026
4:24 PM ET 8-K
Financial Results Armata Pharmaceuticals, Inc. ARMP

Armata Pharmaceuticals Financial Results

Armata Pharmaceuticals reported its third quarter 2026 financial results and provided an update on its AP-SA02 Phase 3 program. The company is finalizing study designs with the FDA and has completed engineering runs at its cGMP manufacturing facility to support the upcoming pivotal trial.

“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02. We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study.”

Dr. Deborah Birx, Chief Executive Officer

“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development.”

Dr. Deborah Birx, Chief Executive Officer
4:24 PM ET 10-Q
Financial Results Innventure, Inc. INV

Innventure Q3 2026 Results: Net Loss of $202M, Loss Widens

Innventure, Inc. reported a significant net loss for the nine months ended September 30, 2026, primarily driven by a $323.5 million goodwill impairment charge. While revenue increased to $3.88 million from $1.23 million year-over-year, the company faces substantial liquidity risks and is exploring strategic alternatives for its subsidiaries AeroFlexx and Refinity.

Key figure
Net loss $202M
4:24 PM ET 8-K
Financial Results FGI Industries Ltd. FGI

FGI Industries Financial Results

FGI Industries reported third quarter 2026 revenue of $31.7 million, an 11.6% year-over-year decline driven by softness in housing and remodeling activity. Despite the revenue drop, gross margin expanded by 110 basis points to 27.6% due to cost discipline and product mix management, though the company recorded a net loss of $0.9 million.

“FGI reported total revenue of $31.7 million in the quarter, representing a year-over-year decline of 11.6%. The quarter reflected a challenging market environment, with continued softness in housing and remodeling activity, reduced customer purchasing and delayed projects weighing on demand across several product categories.”

Dave Bruce, CEO of FGI

“Revenue declined 11.6% year-over-year in the third quarter, reflecting softness in our core North American sanitaryware and shower system categories. Operating expenses remained disciplined, declining on a year-to-date basis, and we continued to advance our commercial pipeline and strengthen sales reporting and account-level performance tracking.”

Jae Chung, Chief Financial Officer of FGI
4:24 PM ET 8-K
Loan & Debt Emerson Electric Co EMR

Emerson Electric $830M Debt Financing with J.P. Morgan Securities plc

Emerson Electric Co. entered into a pricing agreement for a public offering of €750 million aggregate principal amount of 4.000% Notes due 2032. The company expects net proceeds of approximately $830.4 million, which will be used primarily to repay commercial paper borrowings and for general corporate purposes.

Value
$830M
Counterparty
J.P. Morgan Securities plc
Term
through 2032
4:24 PM ET 8-K
Financial Results Xos, Inc. XOS

Xos Financial Results

Xos, Inc. reported its third quarter 2026 financial results, achieving its third consecutive quarter of positive GAAP gross profit and a 17% sequential revenue increase to $5.5 million. Despite a year-over-year revenue decline, the company improved its nine-month GAAP gross margin to 26.9% and reduced operating expenses by 10% through disciplined cost management.

Term
Q3 2026
4:24 PM ET 10-Q
Financial Results Codexis, Inc. CDXS ▶ Call

Codexis Q3 2026 Results: Net Loss of $8.13M, Loss Narrows

Codexis reported a significant increase in total revenues to $19.26 million for Q3 2026, up from $8.60 million in the prior year, driven primarily by product revenue growth. The company successfully reduced its quarterly net loss to $8.13 million compared to $19.62 million in Q3 2025, while strengthening its cash position through a $24.9 million net equity offering.

Key figure
Net loss $8.13M
4:23 PM ET Form 4
Insider Selling Metlife Inc MET

Metlife President & CEO Michel Khalaf Sells $19.3M of Stock

Michel Khalaf, President & CEO, sold 187,425 shares of Metlife Inc at $102.97 a share, worth $19.3M in total on Nov 10, 2026. Shares held after the trade: 759,013 (-19.8%).

Value
$19.3M
Shares
187,425
Price
$102.97
Role
President & CEO
Holding change
-19.8%
Trade date
Nov 10, 2026
4:23 PM ET Form 4
Insider Selling RPM International Inc RPM

RPM International Director Frederick R. Nance Sells $197K of Stock

Frederick R. Nance, Director, sold 1,896 shares of RPM International Inc at $103.97 a share, worth $197K in total on Nov 9, 2026. Shares held after the trade: 7,651 (-19.9%).

Value
$197K
Shares
1,896
Price
$103.97
Role
Director
Holding change
-19.9%
Trade date
Nov 9, 2026
4:23 PM ET 8-K
Nasdaq/NYSE Compliance Notice Rain Enhancement Technologies Holdco, Inc. RAIN

Rain Enhancement Technologies Holdco Nasdaq/NYSE Compliance Notice

Rain Enhancement Technologies Holdco received a deficiency notice from Nasdaq on November 6, 2026, because its Class A common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until May 5, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days.

Counterparty
Nasdaq Listing Qualifications Department
Term
180 days
4:23 PM ET 10-Q
Financial Results Star Equity Holdings, Inc. STRR

Star Equity Holdings Q3 2026 Results: Net Loss of $1.59M, Loss Narrows

Star Equity Holdings, Inc. reported a net loss of $1.59 million for the third quarter of 2026, compared to a $1.76 million loss in the prior year period, despite a 12.4% increase in total revenues to $53.9 million. The company's year-to-date net loss widened significantly to $7.23 million as operating expenses rose, particularly in salaries and general office costs.

Key figure
Net loss $1.59M
4:23 PM ET 10-Q
Financial Results Scribe Therapeutics, Inc. SCTX

Scribe Therapeutics Q3 2026 Results: Net Loss of $9.86M

Scribe Therapeutics reported a net loss of $33.0 million for the nine months ended September 30, 2026, compared to a $12.6 million loss in the prior year period, primarily due to a significant decrease in collaboration revenue. During the quarter, the company completed its initial public offering and concurrent private placement, resulting in a cash and cash equivalents balance of $172.1 million.

Key figure
Net loss $9.86M
4:23 PM ET 10-Q
Financial Results Adams Street Credit Solutions Fund

Adams Street Credit Solutions Fund Q3 2026 Results: Net Income $1.13M, Up 183.2% YoY

Adams Street Credit Solutions Fund (ASCEND) is a business development company that reported 3,326,403.646 Class I shares outstanding as of November 12, 2026. The filing indicates the fund is an emerging growth company and a non-accelerated filer, focusing on middle-market senior loans and secured debt investments.

Key figure
Net income $1.13M · +183.2% YoY
4:23 PM ET Form 4
Insider Selling Pinnacle West Capital Corp PNW

Pinnacle West Capital Insider Paula J. Sims Sells $211K of Stock

Paula J. Sims sold 2,000 shares of Pinnacle West Capital Corp at $105.44 a share, worth $211K in total on Nov 9, 2026. Shares held after the trade: 9,032 (-18.1%).

Value
$211K
Shares
2,000
Price
$105.44
Holding change
-18.1%
Trade date
Nov 9, 2026
4:23 PM ET 10-K
Financial Results Rmr Group Inc. RMR ▶ Call

Rmr Group FY 2026 Results: Net Income $10.7M, Down 39.2% YoY

For the fiscal year ended September 30, 2026, RMR Group Inc. reported total revenues of $643.2 million, an 8.2% decrease from the prior year, primarily driven by lower reimbursable costs. Net income attributable to the company fell 39.2% to $10.7 million, impacted by a $19.1 million impairment loss and increased interest expenses related to new property acquisitions.

Key figure
Net income $10.7M · -39.2% YoY
4:23 PM ET 8-K/A
Executive Compensation Commercial Vehicle Group, Inc. CVGI

Commercial Vehicle Group Executive Compensation

Commercial Vehicle Group, Inc. finalized the specific share counts for inducement equity awards granted to its new President and CEO, David Ruppel. The awards include make-whole grants for forfeited equity from his previous employer and an initial long-term incentive award with a target value of $1.6 million, covering up to 2,175,614 shares at maximum performance.

Counterparty
David Ruppel
Term
through March 2030
4:22 PM ET 10-Q
Financial Results Avidbank Holdings, Inc. AVBH

Avidbank Holdings Q3 2026 Results: Turns Profitable, Net Income $10.2M

Avidbank Holdings reported a significant regulatory shift as of September 30, 2026, with none of its reciprocal deposits classified as brokered deposits due to the 21st Century ROAD to Housing Act. This compares to $475.4 million in brokered deposits at year-end 2025. The company also recorded $1.3 million in bank-owned life insurance death benefits during the first nine months of 2026.

Key figure
Net income $10.2M
4:22 PM ET 8-K
Dividend JLL Income Property Trust, Inc. ZIPTAX

JLL Income Property Trust Dividend

JLL Income Property Trust's Board of Directors declared a monthly distribution for November 2026 of $0.0525 per share and unit. The distribution is payable on or around November 24, 2026, to stockholders of record as of November 19, 2026, representing an annualized distribution rate of approximately 5.6% based on the current NAV.

Term
November 2026
4:22 PM ET 10-Q
Financial Results Solv Energy, Inc. MWH ▶ Call

Solv Energy Q3 2026 Results: Net Income $69.9M, Down 0.3% YoY

SOLV Energy, Inc. is a non-accelerated filer reporting for the quarter ended September 30, 2026. The filing highlights risks related to project timing, labor costs, and material availability, while noting that the company has identified material weaknesses in its internal control over financial reporting.

Key figure
Net income $69.9M · -0.3% YoY
4:22 PM ET 10-Q
Financial Results Principal Credit Real Estate Income Trust

Principal Credit Real Estate Income Trust Q3 2026 Results: Net Income $3.09M, Up 13.7% YoY

Principal Credit Real Estate Income Trust reported net income of $6.93 million for the nine months ended September 30, 2026, a significant increase from $2.15 million in the prior year period. Total assets grew to $494.7 million, driven by investments in loans receivable, while the company continued to issue multiple classes of common shares to fund its real estate credit activities.

Key figure
Net income $3.09M · +13.7% YoY
4:22 PM ET 8-K
Financial Results Ensysce Biosciences, Inc. ENSC

Ensysce Biosciences Financial Results

Ensysce Biosciences reported financial results for the third quarter of 2026, highlighting the completion of its acquisition of Cy Biopharma and the addition of lead asset CY200 for Complex Regional Pain Syndrome. The company ended the quarter with a strengthened cash position of $29.7 million and submitted a Phase 2a protocol for CY200 to the UK's MHRA.

Term
Q3 2026

“Ensysce is a fundamentally different company today than it was at the start of the year. With CY200, we now lead with a potentially first-in-class approach to CRPS, a devastating condition for which there is currently no FDA-approved therapy.”

Dr. Lynn Kirkpatrick, Chief Executive Officer

“Our priority since the acquisition has been to advance CY200 efficiently, and submitting the CYBIO 001 protocol to the MHRA in September was a significant first step.”

James Morrison, President of Ensysce
4:22 PM ET Form 4
Insider Selling Aeva Technologies, Inc. AEVA

Aeva Technologies CTO Mina Rezk Sells $604K of Stock

Mina Rezk, CTO, sold 50,000 shares of Aeva Technologies, Inc. at $11.33 to $12.19 a share (average $12.08) in 2 transactions, worth $604K in total on Nov 9, 2026. Shares held after the trade: 1,556,669 (-2.7%).

Value
$604K
Shares
50,000
Average price
$12.08
Role
CTO
Holding change
-2.7%
Trade date
Nov 9, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.